Carla Rovirosa Martí
Tècnic/a de laboratori
Grup de recerca
Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study.
Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals.
Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities.
Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection.